C4 Therapeutics (CCCC) Cash from Investing Activities Growth (1y) (2020 - 2026)
C4 Therapeutics (CCCC) Cash from Investing Activities Growth (1y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 62.68% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -674.01% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -166.24% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | C4 Therapeutics | 457.02 Mn | 221.35 Mn | - | -44.54% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -44.54% |
| Dec 31, 2025 | -690.59% |
| Sep 30, 2025 | 2,422.22% |
| Jun 30, 2025 | 432.49% |
| Mar 31, 2025 | 154.55% |
| Dec 31, 2024 | -57.21% |
| Sep 30, 2024 | -99.72% |
| Jun 30, 2024 | -177.28% |
| Mar 31, 2024 | -199.75% |
| Dec 31, 2023 | 244.09% |
| Sep 30, 2023 | 189.87% |
| Jun 30, 2023 | -54.41% |
| Mar 31, 2023 | 1,436.94% |
| Dec 31, 2022 | 115.63% |
| Sep 30, 2022 | 119.79% |
| Jun 30, 2022 | 2.45% |
| Mar 31, 2022 | 93.51% |
| Dec 31, 2021 | -9.68% |
| Sep 30, 2021 | -211.34% |
| Jun 30, 2021 | 131.24% |